OBJECTIVE: Previous study findings have suggested that patients with chronic diseases such as rheumatoid arthritis (RA) do not receive optimal preventive medical services, including cancer screening tests. This study was undertaken to evaluate cancer screening rates in RA patients compared to non-RA control populations. METHODS: Using data from a large US commercial insurance plan, we examined rates of screening tests for cervical, breast, and colon cancer in patients with RA compared to control subjects without RA (non-RA controls) or control subjects with hypertension. Individuals were included in the RA cohort if they had at least 2 visits coded for a diagnosis of RA and had received at least 1 prescription for a disease-modifying antirheumatic drug during the study period. Multivariable Cox proportional hazards models were used to compare the rates of different cancer screening tests between RA patients and non-RA controls. RESULTS: RA patients (n = 13,314) and control subjects (non-RA and hypertension controls) (n = 212,324) were screened, on average, once every 3 years for cervical cancer and once every 2 years for breast cancer during the followup period (mean 2.3 years of followup). In the age-adjusted Cox regression model, women with RA were more likely to receive ≥ 1 Papanicolaou smear (hazard ratio [HR] 1.21, 95% confidence interval [95% CI] 1.17-1.24), ≥ 1 mammogram (HR 1.49, 95% CI 1.45-1.53), and ≥ 1 colonoscopy (HR 1.69, 95% CI 1.61-1.77) compared to female non-RA control subjects. Men with RA were also more likely to receive at least 1 colonoscopy (HR 1.52, 95% CI 1.40-1.64) than were male non-RA control subjects. These results were robust in multivariable analyses adjusted for age, number of physician visits, percentage of visits made to primary care physicians, and the Charlson Comorbidity Index. CONCLUSION: Patients with RA did not appear to be at risk for receiving fewer cancer screening tests when compared to individuals without RA. The majority of both RA patients and non-RA control subjects were screened regularly for cervical, breast, and colon cancer, in accordance with current recommendations.
OBJECTIVE: Previous study findings have suggested that patients with chronic diseases such as rheumatoid arthritis (RA) do not receive optimal preventive medical services, including cancer screening tests. This study was undertaken to evaluate cancer screening rates in RApatients compared to non-RA control populations. METHODS: Using data from a large US commercial insurance plan, we examined rates of screening tests for cervical, breast, and colon cancer in patients with RA compared to control subjects without RA (non-RA controls) or control subjects with hypertension. Individuals were included in the RA cohort if they had at least 2 visits coded for a diagnosis of RA and had received at least 1 prescription for a disease-modifying antirheumatic drug during the study period. Multivariable Cox proportional hazards models were used to compare the rates of different cancer screening tests between RApatients and non-RA controls. RESULTS:RApatients (n = 13,314) and control subjects (non-RA and hypertension controls) (n = 212,324) were screened, on average, once every 3 years for cervical cancer and once every 2 years for breast cancer during the followup period (mean 2.3 years of followup). In the age-adjusted Cox regression model, women with RA were more likely to receive ≥ 1 Papanicolaou smear (hazard ratio [HR] 1.21, 95% confidence interval [95% CI] 1.17-1.24), ≥ 1 mammogram (HR 1.49, 95% CI 1.45-1.53), and ≥ 1 colonoscopy (HR 1.69, 95% CI 1.61-1.77) compared to female non-RA control subjects. Men with RA were also more likely to receive at least 1 colonoscopy (HR 1.52, 95% CI 1.40-1.64) than were male non-RA control subjects. These results were robust in multivariable analyses adjusted for age, number of physician visits, percentage of visits made to primary care physicians, and the Charlson Comorbidity Index. CONCLUSION:Patients with RA did not appear to be at risk for receiving fewer cancer screening tests when compared to individuals without RA. The majority of both RApatients and non-RA control subjects were screened regularly for cervical, breast, and colon cancer, in accordance with current recommendations.
Authors: Sarathchandra I Reddy; Sonia Friedman; Jennifer J Telford; Lisa Strate; Rie Ookubo; Peter A Banks Journal: Am J Gastroenterol Date: 2005-06 Impact factor: 10.864
Authors: Hilal Maradit Kremers; Michelle Bidaut-Russell; Christopher G Scott; Megan S Reinalda; Alan R Zinsmeister; Sherine E Gabriel Journal: J Rheumatol Date: 2003-09 Impact factor: 4.666
Authors: Seo Young Kim; Amber Servi; Jennifer M Polinski; Helen Mogun; Michael E Weinblatt; Jeffrey N Katz; Daniel H Solomon Journal: Arthritis Res Ther Date: 2011-02-23 Impact factor: 5.156
Authors: E Kathleen Adams; A Rana Bayakly; Alissa K Berzen; Sarah Blake; Peter Joski; Chunyu Li; Ingrid J Hall; Susan A Sabatino Journal: Cancer Causes Control Date: 2015-03-27 Impact factor: 2.506
Authors: Seoyoung C Kim; Sebastian Schneeweiss; Jun Liu; Elizabeth W Karlson; Jeffrey N Katz; Sarah Feldman; Daniel H Solomon Journal: Arthritis Rheumatol Date: 2016-09 Impact factor: 10.995
Authors: Carrie N Klabunde; Yingye Zheng; Virginia P Quinn; Elisabeth F Beaber; Carolyn M Rutter; Ethan A Halm; Jessica Chubak; Chyke A Doubeni; Jennifer S Haas; Aruna Kamineni; Marilyn M Schapira; Pamela M Vacek; Michael P Garcia; Douglas A Corley Journal: Am J Prev Med Date: 2016-06-22 Impact factor: 5.043
Authors: Maxime Dougados; Martin Soubrier; Anna Antunez; Peter Balint; Alejandro Balsa; Maya H Buch; Gustavo Casado; Jacqueline Detert; Bassel El-Zorkany; Paul Emery; Najia Hajjaj-Hassouni; Masayoshi Harigai; Shue-Fen Luo; Reka Kurucz; Gabriel Maciel; Emilio Martin Mola; Carlo Maurizio Montecucco; Iain McInnes; Helga Radner; Josef S Smolen; Yeong-Wook Song; Harald Erwin Vonkeman; Kevin Winthrop; Jonathan Kay Journal: Ann Rheum Dis Date: 2013-10-04 Impact factor: 19.103